Wolfe Research analyst Kalpit Patel initiated coverage of Soleno Therapeutics (SLNO) with an Outperform rating and $75 price target Shares have been weak following a slowing of new patient starts quarter-over-quarter, but the firm’s survey results suggest that the safety concerns are “overblown” and the directional trend for utilization is favorable for the next one to two years, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics Announces $100M Share Buyback Plan
- Soleno board authorizes $100M Accelerated Share Repurchase Agreement
- Soleno Therapeutics: Strong Q3 Performance and Market Potential Justify Buy Rating
- Soleno Therapeutics’ Financial Challenges: Navigating Risks in VYKAT XR Commercialization
- Soleno Therapeutics’ Earnings Call Highlights Growth Amid Challenges